Benjamin F. McGraw, III, Pharm.D. (Chair of Board)

Dr. Benjamin F. McGraw is Executive Chairman of Perfuse Therapeutics, a clinical-stage biopharmaceutical company committed to reducing the incidence of blindness. He is also a Director at TheraVida, a private pharmaceutical company focused on therapies for dermatologic diseases, Executive Chairman of Auration Biotech, a private biotechnology company focused on a regenerative protein and other therapies for ear, nose, and throat diseases and the Chairman of Trefoil Therapeutics, a private biopharmaceutical company focused on developing an engineered protein as a regenerative treatment for corneal endothelial dystrophies and epithelial disorders. Previously, Dr. McGraw served as Chairman of Aerie Pharmaceuticals, a public pharmaceutical company focused on ophthalmology, the Managing Member of Long Shadows Asset Management, LLC, an investment advisory company; Chairman, President, and CEO of Valentis, a public gene therapy company; Vice President of Corporate Development at Allergan, a public pharmaceutical company; and Vice President of Development at Marion Laboratories, and Marion Merrell Dow, both public pharmaceutical companies. Dr. McGraw received his BS degree and his PharmD from the University of Tennessee Health Science Center, where he also completed a clinical practice residency.